PL2104682T3 - Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych - Google Patents

Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych

Info

Publication number
PL2104682T3
PL2104682T3 PL08719192T PL08719192T PL2104682T3 PL 2104682 T3 PL2104682 T3 PL 2104682T3 PL 08719192 T PL08719192 T PL 08719192T PL 08719192 T PL08719192 T PL 08719192T PL 2104682 T3 PL2104682 T3 PL 2104682T3
Authority
PL
Poland
Prior art keywords
alzheimer
diagnosis
treatment
neurodementing
diseases
Prior art date
Application number
PL08719192T
Other languages
English (en)
Inventor
Richard Dodel
Michael Bacher
Michael Przybylski
Raluca Stefanescu
Marilena Manea
Original Assignee
Michael Bacher
Dodel, Richhard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07000521A external-priority patent/EP1944315A1/en
Priority claimed from EP07000507A external-priority patent/EP1944314A1/en
Application filed by Michael Bacher, Dodel, Richhard filed Critical Michael Bacher
Publication of PL2104682T3 publication Critical patent/PL2104682T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL08719192T 2007-01-11 2008-01-11 Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych PL2104682T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US88452607P 2007-01-11 2007-01-11
US88451307P 2007-01-11 2007-01-11
EP07000521A EP1944315A1 (en) 2007-01-11 2007-01-11 Prophylaxis and therapy of alzheimer's disease and other neurodementing diseases
EP07000507A EP1944314A1 (en) 2007-01-11 2007-01-11 Diagnosis of Alzheimer's disease and other neurodementing disorders
US98166707P 2007-10-22 2007-10-22
US98167507P 2007-10-22 2007-10-22
EP07119002 2007-10-22
EP07119026 2007-10-22

Publications (1)

Publication Number Publication Date
PL2104682T3 true PL2104682T3 (pl) 2017-03-31

Family

ID=39609117

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08719192T PL2104682T3 (pl) 2007-01-11 2008-01-11 Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych

Country Status (11)

Country Link
US (3) US7939075B2 (pl)
EP (1) EP2104682B1 (pl)
JP (1) JP2010515717A (pl)
AU (1) AU2008204335B2 (pl)
CA (1) CA2675340C (pl)
DK (1) DK2104682T3 (pl)
ES (1) ES2610474T3 (pl)
PL (1) PL2104682T3 (pl)
SI (1) SI2104682T1 (pl)
TW (1) TW200844110A (pl)
WO (1) WO2008084402A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280114A1 (en) * 2002-04-12 2009-11-12 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
JP5475994B2 (ja) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2143447A1 (en) * 2008-07-11 2010-01-13 Universität Konstanz Bioconjugates comprising Aß-autoantibody-specific epitopes for active immunotherapy and diagnosis of Alzheimer's disease
NZ616673A (en) * 2009-02-20 2014-08-29 To Bbb Holding B V Glutathione-based drug delivery system
KR101095630B1 (ko) * 2009-06-17 2011-12-19 주식회사 이노파마스크린 베타 아밀로이드 펩타이드와 ｖｅｇｆ의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제
DE102009034119A1 (de) * 2009-07-20 2011-01-27 Philipps-Universität Marburg Verfahren, insbesondere Enzyme-linked Immunosorbent Assay (ELISA), zum in vitro Nachweis von Amyloid beta Autoantikörpern, Mikrotiterplatte und Testkit
WO2011017600A2 (en) 2009-08-07 2011-02-10 American Life Science Pharmaceuticals, Inc. (Alsp Inc.) Compositions and methods for treating beta-amyloid related diseases
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
DK2579042T3 (da) * 2011-10-04 2014-07-21 Affiris Ag Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve
KR101190573B1 (ko) * 2011-10-07 2012-10-18 대한민국 혈액 내 아밀로이드-베타 항체에 특이적으로 결합하는 신규 Ａβ２２（ｐＥ）－４２ 펩티드를 유효성분으로 포함하는 치매 진단용 키트
JP2015511014A (ja) * 2012-03-13 2015-04-13 ヤンセン アルツハイマー イミュノセラピー アルツハイマー病の診断、予後および監視におけるオリゴマー型Ａβ
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
JP6582995B2 (ja) * 2014-01-21 2019-10-02 株式会社島津製作所 Ａｐｐ切断型ペプチドの測定方法
WO2015121339A1 (en) * 2014-02-14 2015-08-20 RUHR-UNIVERSITäT BOCHUM Biosensor for conformation and secondary structure analysis
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
EP3043354B1 (en) * 2015-01-12 2018-01-03 Heraeus Deutschland GmbH & Co. KG Use of an electrically conductive composition as an electrically conductive adhesive for mechanically and electrically connecting electrical conductors to electrical contacts of solar cells
ES2834484T3 (es) 2016-11-21 2021-06-17 Univ Ruhr Bochum Método para la preselección de fármacos para enfermedades de plegamiento incorrecto de proteínas
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CA3085785A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-lrp5/6 antibodies and methods of use
EP4603508A3 (en) 2017-12-19 2025-10-29 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
CA3085782A1 (en) * 2017-12-19 2019-06-27 Surrozen, Inc. Wnt surrogate molecules and uses thereof
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
AU2021379770A1 (en) 2020-11-16 2023-06-22 Surrozen Operating, Inc. Liver-specific wnt signal enhancing molecules and uses thereof
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
AR133829A1 (es) 2023-09-15 2025-11-05 Othair Prothena Ltd Agentes penetrantes de células y usos de los mismos

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
EP1308461A3 (en) 1993-01-25 2004-02-11 Takeda Chemical Industries, Ltd. Antibodies to beta-amyloids or their derivatives and use thereof
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP2006303A1 (en) 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
IL149976A0 (en) 1999-12-08 2002-12-01 Mindset Biopharmaceuticals Usa Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
US20030083277A1 (en) 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
KR20060088905A (ko) * 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US20050208050A1 (en) 2001-11-09 2005-09-22 Gerd Multhaup Compounds for the diagnosis/prevention/treatment of alzheimer's disease
US20050227941A1 (en) 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004013172A2 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
ATE506072T1 (de) 2002-09-12 2011-05-15 Univ California Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
EP1545582A4 (en) 2002-10-01 2008-09-17 Univ Northwestern DIFFUSIBLE DERIVATIVES DERIVED FROM AMYLOID BETA (ADDL), ADDL SUBSTITUTE, ADDL BINDING MOLECULES, AND USES THEREOF
PL377769A1 (pl) 2002-10-09 2006-02-20 Rinat Neuroscience Corp. Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje
US20050106626A1 (en) 2002-10-20 2005-05-19 George Pieczenik Ligand binding of amyloid peptide protein epitope
ES2401136T3 (es) * 2002-11-15 2013-04-17 Genmab A/S Anticuerpos monoclonales humanos contra CD25
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20070031416A1 (en) 2003-09-09 2007-02-08 Takeda Pharmaceutical Company Limited Use of antibody
US20070110750A1 (en) 2003-09-12 2007-05-17 The Regents Of The University Of California Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
BRPI0417023A (pt) * 2003-11-28 2007-02-21 Astrazeneca Ab anticorpo ou fragmento de anticorpo humanos, uso dos mesmos, composição farmacêutica, métodos para tratar um paciente que sofre de um distúrbio amilóide, para diagnosticar um distúrbio amilóide em um paciente, e para detectar a presença do apoe-ctd em uma amostra de um paciente, polinucleotìdeo, vetor, célula hospedeira, vìrus, e, kit para detectar apoe-ctd
BRPI0507856A (pt) 2004-02-23 2007-07-10 Lilly Co Eli composição farmacêutica, e, processo para preparar o anticorpo abeta
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP1781328A4 (en) 2004-07-10 2009-06-03 Alexion Pharma Inc METHOD FOR DETECTING SPECIFIC ANTIBODIES TO CANCER CELLS AND ANTIBODIES SOUND
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
US20080044356A1 (en) 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
US7780963B2 (en) 2004-10-25 2010-08-24 Merck & Co., Inc. Anti-ADDL antibodies and uses thereof
TW200635608A (en) * 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
CN105085678B (zh) * 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
CN101111264A (zh) 2005-01-28 2008-01-23 惠氏公司 稳定化的液体多肽制剂
CA2599792A1 (en) 2005-03-05 2006-09-14 Abbott Gmbh & Co. Kg Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
US9133267B2 (en) 2005-11-22 2015-09-15 The Trustees Of The University Of Pennsylvania Antibody treatment of Alzheimer's and related diseases
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
NO347079B1 (no) 2006-03-23 2023-05-08 Bioarctic Neuroscience Ab Forbedrede protofibrilselektive antistoffer og anvendelse derav
US8168185B2 (en) * 2007-01-17 2012-05-01 Merck Serono Sa Process for the purification of anti CD-25 antibodies
WO2009099176A1 (ja) * 2008-02-08 2009-08-13 Immunas Pharma, Inc. Aβオリゴマーに特異的に結合する抗体およびその利用

Also Published As

Publication number Publication date
SI2104682T1 (sl) 2017-05-31
TW200844110A (en) 2008-11-16
US20090028869A1 (en) 2009-01-29
EP2104682A2 (en) 2009-09-30
US20120040382A1 (en) 2012-02-16
CA2675340C (en) 2018-07-31
WO2008084402A2 (en) 2008-07-17
ES2610474T3 (es) 2017-04-27
US20120039897A1 (en) 2012-02-16
CA2675340A1 (en) 2008-07-17
AU2008204335B2 (en) 2013-06-13
WO2008084402A8 (en) 2009-08-27
US7939075B2 (en) 2011-05-10
WO2008084402A3 (en) 2009-04-09
DK2104682T3 (en) 2017-01-16
AU2008204335A1 (en) 2008-07-17
US8491903B2 (en) 2013-07-23
EP2104682B1 (en) 2016-09-21
JP2010515717A (ja) 2010-05-13

Similar Documents

Publication Publication Date Title
PL2104682T3 (pl) Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
IL208926A0 (en) Use of epothelone d in treating tau-associated diseases including alzheimer's disease
EP2429992A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
EP2369017B8 (en) Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
ZA200801511B (en) Novel diazaspiroalkanes and their use for treatment of CCR8 medicated diseases
EP2152318A4 (en) COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
EP2091566A4 (en) COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES
EP2151435A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
SI2056842T1 (sl) Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
EP2306824A4 (en) IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
PT2056863T (pt) Tratamento de doenças oculares
EP2051732A4 (en) DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR
PL1981515T3 (pl) Leczenie urazów i chorób mózgu za pomocą MAPC
EP2568811A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
EP2206714A4 (en) AGENT FOR THE PREVENTION AND / OR TREATMENT OF SKIN DISEASES
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
WO2010105035A9 (en) Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
IL213703A (en) Compounds for the treatment of pain and other diseases
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
GB0608647D0 (en) Methods of diagnosis and treatment
EP1773882A4 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6
ZA200904755B (en) Use of epothilones in the treatment of osteoporosis and related diseases
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
EP2099476A4 (en) METHODS OF TREATING ALZHEIMER'S DISEASE
EP1846013A4 (en) TREATMENT OF SKIN DISEASES